MarketCapExport financials
OptimizeRx Corporation (OPRX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
OptimizeRx Corporation Income Statement 2025-2010 | OPRX
Brief overview of financial performance at OptimizeRx Corporation
This overview is based on financial performance over the past five years. According to figures from OptimizeRx Corporation, revenue changed from 43.3 million dollars to 109 million dollars over five years. Overall revenue changed by +152.6%, equal to an annualized rate of about 20.4%. The annual growth rate indicates an exceptionally strong top-line trend.
Gross profit changed from $24.1 million to $73.6 million (+205.3%). The cost base moved more slowly than the top line, which supported margins. At the margin level, the figure shifted from 55.7% to 67.3%. The business retained more gross profit from each unit of revenue.
EBITDA changed from −59.4 thousand dollars to 16 million dollars (+27055.6%). The operating result outpaced sales and points to improving efficiency. The EBITDA share of revenue changed from −0.1% to 14.6%. The increased EBITDA share is a positive sign.
Comparing the endpoints shows a move from −$2.2 million to $5.1 million. A negative result turned positive over the five years.
Over the period, capitalization shifted from $669 million to $229 million (−65.8%). Financial performance is stronger than the share-price trend.
Summary assessment
The figures do not all move in the same direction. The positive side is supported by better sales economics, higher operating efficiency and sales growth. The weaker side of the profile includes declining capitalization. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement OptimizeRx Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
229 M | 214 M | 177 M | 237 M | 774 M | 669 M | 151 M | 119 M | 41.5 M | 23.8 M | 26.5 M | 23.7 M | 26.9 M | 14.9 M | 11.1 M | - |
Shares |
18.6 M | 18.3 M | 17.1 M | 17.8 M | 17.2 M | 14.8 M | 13.4 M | 10.8 M | 9.82 M | 9.9 M | 8.19 M | 7.46 M | 4.8 M | 4.74 M | 4.64 M | - |
Historical Prices |
12.4 | 11.7 | 10.3 | 13.3 | 44.9 | 45.1 | 11.1 | 11.2 | 4.11 | 2.31 | 3.24 | 3.18 | 5.61 | 3.15 | 2.4 | 5.85 |
Net Income |
5.13 M | -20.1 M | -17.6 M | -11.4 M | 378 K | -2.21 M | -3.14 M | 226 K | -2.1 M | -1.54 M | -595 K | -1.03 M | 216 K | -364 K | -2.12 M | -2.01 M |
Revenue |
109 M | 92.1 M | 71.5 M | 62.5 M | 61.3 M | 43.3 M | 24.6 M | 21.2 M | 12.1 M | 7.75 M | 7.22 M | 6.5 M | 4.96 M | 2.05 M | 1.11 M | 71.1 K |
Cost of Revenue |
35.8 M | 32.7 M | 28.6 M | 23.5 M | 25.7 M | 19.2 M | 9.16 M | 9 M | - | - | - | - | - | - | - | - |
Gross Profit |
73.6 M | 59.4 M | 42.9 M | 39 M | 35.6 M | 24.1 M | 15.4 M | 12.2 M | 5.95 M | 4.34 M | 3.6 M | 3.28 M | 3.19 M | 2.05 M | 1.11 M | - |
Operating Income |
11.7 M | -13.7 M | -26.4 M | -12.3 M | 361 K | -2.14 M | -3.69 M | 180 K | -2.13 M | -1.58 M | -597 K | -1.03 M | -268 K | -455 K | -1.45 M | -1.85 M |
Interest Expense |
- | - | 1.45 M | 852 K | 17 K | -71.8 K | -347 K | 46.2 K | - | - | - | - | - | 100 | -959 K | -107 K |
EBITDA |
16 M | -9.38 M | -24 M | -10.3 M | 2.33 M | -59.4 K | -1.61 M | 1.1 M | -1.81 M | -1.3 M | -263 K | -362 K | 410 K | -177 K | -1.31 M | -1.79 M |
Operating Expenses |
61.9 M | 73.1 M | 69.3 M | 51.3 M | 35.3 M | 26.2 M | 18.3 M | 11.4 M | 8.08 M | 5.87 M | 4.2 M | 3.91 M | 2.97 M | 2.41 M | 2.57 M | 1.92 M |
General and Administrative Expenses |
50.2 M | 49.8 M | 44.3 M | 744 K | 27.7 M | 21 M | 13.5 M | 9.99 M | 6.54 M | 4.94 M | 3.27 M | 3.37 M | 2.73 M | 2.17 M | 2.02 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement OptimizeRx Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
18.5 M | 18.8 M | - | 18.6 M | 18.5 M | 18.5 M | 18.5 M | 18.3 M | 18.3 M | 18.2 M | 18.2 M | 16.6 M | 17 M | 17.1 M | 18.3 M | 18 M | 18.1 M | 17.9 M | 17.9 M | 17.6 M | 17.3 M | 16.1 M | 15.2 M | 14.9 M | 14.7 M | 14.6 M | 14.6 M | 14.1 M | 12.7 M | 12.1 M | 12 M | 11.8 M | 11 M | 9.79 M | 9.77 M | 9.75 M | 9.86 M | 29.7 M | 29.7 M | 29.4 M | 29.1 M | 29 M | 29 M | 23.3 M | 22.9 M | 22.9 M | 22.9 M | 23.4 M | 23.2 M | 16.7 M | 14.8 M | 14.2 M | 33.6 M | 14.2 M | - | 14.2 M | 14.2 M | - | - | - | - | - |
Net Income |
-2.2 M | -495 K | - | 779 K | 1.53 M | -2.2 M | - | -9.12 M | -4.01 M | -6.9 M | - | -2.86 M | -4.16 M | -6.4 M | - | -3.47 M | -3.88 M | -3.76 M | - | 39.9 K | 352 K | -637 K | - | -283 K | -1.08 M | -2.2 M | - | -1.57 M | 407 K | 6.53 K | - | 245 K | 281 K | -189 K | - | -623 K | -362 K | -883 K | - | -243 K | -592 K | -352 K | - | 87.9 K | -157 K | -111 K | - | -295 K | -199 K | -762 K | - | -412 K | -248 K | -224 K | - | -483 K | -377 K | -301 K | - | -2.03 M | -433 K | -380 K |
Revenue |
29.2 M | 19.8 M | - | 26.1 M | 29.2 M | 21.9 M | - | 21.3 M | 18.8 M | 19.7 M | - | 16.3 M | 13.8 M | 13 M | - | 15.1 M | 14 M | 13.7 M | - | 16.1 M | 13.6 M | 11.2 M | - | 10.5 M | 8.78 M | 7.58 M | - | 5 M | 7.01 M | 5.21 M | - | 5.42 M | 5.1 M | 2.78 M | - | 3.1 M | 2.87 M | 1.4 M | - | 1.79 M | 1.91 M | 1.76 M | - | 2.01 M | 1.71 M | 1.49 M | - | 1.82 M | 1.43 M | 1.29 M | - | 1.37 M | 1.1 M | 669 K | - | 77 | 146 | 185 | - | 206 | 395 | 440 |
Cost of Revenue |
10.6 M | 4.91 M | - | 8.55 M | 10.6 M | 8.58 M | - | 7.86 M | 7.11 M | 7.49 M | - | 6.53 M | 5.99 M | 5.57 M | - | 5.66 M | 4.99 M | 5.63 M | - | 7.05 M | 5.58 M | 5.1 M | - | 4.5 M | 3.64 M | 3.24 M | - | 1.98 M | 2.69 M | 1.58 M | - | 2.27 M | 2.24 M | 2.01 M | - | - | - | 1.38 M | - | - | - | 893 K | - | - | - | - | - | 859 K | - | - | - | 529 K | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 17.5 M | 18.6 M | 13.3 M | - | 13.4 M | 11.7 M | 12.2 M | - | 9.8 M | 7.82 M | 7.43 M | - | 9.42 M | 8.99 M | 8.1 M | - | 9.08 M | 8.04 M | 6.12 M | - | 6.01 M | 5.14 M | 4.34 M | - | 3.02 M | 4.32 M | 3.63 M | - | 3.15 M | 2.86 M | 2.1 M | - | 1.4 M | 1.26 M | 770 K | - | 1.06 M | 990 K | 867 K | - | 963 K | 823 K | 731 K | - | 861 K | 697 K | 728 K | - | 844 K | 1.04 M | 653 K | - | - | - | - | - | - | - | - |
Operating Income |
3.21 M | 396 K | - | 2.05 M | 3.19 M | -2.11 M | - | -8.56 M | -3.75 M | -5.03 M | - | -3.55 M | -4.85 M | -7.06 M | - | -3.76 M | -3.91 M | -3.76 M | - | 38.2 K | 340 K | -638 K | - | -177 K | -1.06 M | -2.26 M | - | -1.99 M | 480 K | 132 K | - | 223 K | 274 K | -191 K | - | -630 K | -371 K | -890 K | - | -249 K | -603 K | -362 K | - | 87.6 K | -158 K | -111 K | - | -295 K | -200 K | -762 K | - | -142 K | 354 K | 99.8 K | - | -106 K | -76.2 K | -301 K | - | 13.5 M | -420 K | -240 K |
Interest Expense |
- | - | - | - | - | - | - | - | - | 1.55 M | - | 688 K | 720 K | 665 K | - | 290 K | 23.8 K | 3 | - | 1.7 K | 12 K | 931 | - | -106 K | -21.7 K | 55.3 K | - | 416 K | -73.4 K | -126 K | - | - | - | - | - | - | - | - | - | 163 | 163 | 163 | - | - | - | - | - | - | - | - | - | - | - | - | - | -100 | - | - | - | -679 K | -140 K | -140 K |
EBITDA |
4.26 M | 1.46 M | - | 3.13 M | 4.26 M | -1.02 M | - | -7.47 M | -2.68 M | -3.96 M | - | -3.09 M | -4.38 M | -6.6 M | - | -3.24 M | -3.33 M | -3.29 M | - | 1.62 M | 1.39 M | -638 K | - | -177 K | -1.06 M | -1.74 M | - | -1.24 M | 906 K | 322 K | - | 387 K | 383 K | -137 K | - | -417 K | -229 K | -819 K | - | -95.2 K | -501 K | -312 K | - | 330 K | 1.81 K | -31.8 K | - | -112 K | -84 K | -703 K | - | -93.4 K | 402 K | 148 K | - | -59.4 K | -28.9 K | -255 K | - | 13.5 M | -390 K | -210 K |
Operating Expenses |
- | - | - | 15.5 M | 15.4 M | 15.5 M | - | 22 M | 15.5 M | 17.2 M | - | 13.4 M | 12.7 M | 14.5 M | - | 13.2 M | 12.9 M | 11.9 M | - | 9.04 M | 7.7 M | 6.76 M | - | 6.19 M | 6.2 M | 6.6 M | - | 5.01 M | 3.84 M | 3.49 M | - | 2.92 M | 2.59 M | 2.3 M | - | 2.03 M | 1.63 M | 1.66 M | - | 1.31 M | 1.59 M | 1.23 M | - | 875 K | 981 K | 843 K | - | 1.16 M | 897 K | 1.49 M | - | 1.08 M | 750 K | 553 K | - | 559 K | 592 K | 630 K | - | 601 K | 621 K | 634 K |
General and Administrative Expenses |
3.91 M | 3.51 M | - | 14.4 M | 14.4 M | 14.4 M | - | 13.4 M | 14.4 M | 16.2 M | - | 12.9 M | 12.2 M | 14 M | - | 12.7 M | 12.3 M | 11.4 M | - | 3.41 M | 2.9 M | 2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 89.3 K | - | 94.8 K | 56.5 K | 219 K | - | 63.2 K | 57.1 K | 77 K | - | 133 K | 101 K | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company OptimizeRx Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B |  USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
So-Young International
SY
|
$ 2.07 | -1.2 % | $ 161 M |  China |
 |
Veeva Systems
VEEV
|
$ 303.83 | -2.03 % | $ 49.7 B | USA |
 |
SCWorx Corp.
WORX
|
$ 7.25 | 31.34 % | $ 52.7 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.96 | -0.08 % | $ 3.28 M | China |
 |
HealthStream
HSTM
|
$ 28.84 | -1.76 % | $ 866 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
10x Genomics
TXG
|
$ 58.86 | 1.38 % | $ 7.34 B | USA |
 |
American Well Corporation
AMWL
|
$ 11.95 | -1.24 % | $ 192 M | USA |
 |
Evolent Health
EVH
|
$ 4.58 | 0.77 % | $ 523 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.52 | 0.86 % | $ 1.25 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.47 | -2.0 % | $ 103 M | USA |
 |
HealthEquity
HQY
|
$ 103.6 | 0.13 % | $ 8.92 B | USA |
 |
Omnicell
OMCL
|
$ 37.35 | -1.77 % | $ 1.72 B | USA |
 |
Progyny
PGNY
|
$ 34.88 | 1.48 % | $ 2.97 B | USA |
 |
Schrödinger
SDGR
|
$ 29.8 | 3.58 % | $ 2.19 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.85 | -6.2 % | $ 1.56 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Phreesia
PHR
|
$ 12.62 | -0.71 % | $ 754 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |